Glucagon-like peptide-1 (GLP-1) compounds have emerged as a compelling therapeutic strategy for managing metabolic syndromes. These naturally occurring substances are secreted by the gut in response to nutrient intake, stimulating insulin secretion and suppressing glucagon output. GLP-1 peptides possess promising therapeutic outcomes in treating ty